Last update Dec. 21, 2022

Didanosine (DDI)

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Antiretroviral. It is a nucleoside reverse transcriptase inhibitor (NRTI) with antiviral activity against HIV-1. Indicated for the treatment of HIV infection and AIDS. Administration together with other oral antiretrovirals in one or two daily doses.

At the date of the last update we did not find any published data on its excretion in breast milk.

It has been used to treat children older than 3 mo of age. 

The most common serious adverse effects of didanosine are peripheral neuropathy and life-threatening pancreatitis. Other frequently reported adverse effects are abdominal pain, diarrhea, fatigue, headache, nausea, rash, and vomiting. (Martindale)

During breastfeeding, other HIV/AIDS treatments are preferable. (Panel 2022, WHO 2016)


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Didanosine (DDI) in other languages or writings:

Group

Didanosine (DDI) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Didanosine (DDI) in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 42 ± 12 %
Molecular weight 236 daltons
Protein Binding < 5 %
VD 4 ± 2 l/Kg
pKa 10.9 -
Tmax 0.5 - 1.5 hours
1.2 ± 0.2 hours

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. Royal Pharmaceutical Society. Martindale: The Complete Drug Reference Medicines Complete. available online from: https://www.medicinescomplete.com 2022 Abstract
  3. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)

Total visits

3,376

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM